Hutchmed (China) (HCM) said late Monday it completed enrollment in the registration phase of a phase II trial to assess the efficacy, safety and tolerability of savolitinib in gastric cancer patients with MET amplification.

A total of 64 patients have been enrolled in the trial.

If positive, the company may begin plans to apply for marketing authorization of savolitinib for gastric cancer in China later this year, it said.

Savolitinib is being jointly developed by AstraZeneca (AZN) and Hutchmed, and commercialized by AstraZeneca.